MRI cardiopulmonary metrics in pulmonary arterial hypertension
Research type
Research Study
Full title
Reproducibility of Magnetic resonance imaging cardiopulmonary metrics in healthy volunteers and patients with pulmonary arterial hypertension – Implications for trial design
IRAS ID
172358
Contact name
Andrew Swift
Contact email
Sponsor organisation
Sheffield Teaching Hospitals NHS Foundation Trust
Duration of Study in the UK
1 years, 10 months, 24 days
Research summary
Pulmonary arterial hypertension (PAH) is a progressive life limiting disease with a median survival of less than 3 years without treatment. Current drug trials in PAH commonly use simple tests, for example the 6-minute walk test, blood tests, and invasive tests to measure the function of the heart. There is now evidence suggesting that magnetic resonance Imaging (MRI) may be more helpful in the follow up of patients with PAH to identify patients who are not benefiting from treatment. This is because MRI can track changes by directly seeing the heart beating allowing measurments to be made, which is an advantage over existing methods. However, whether the results are the same if the scan is repeated, or if 2 people to analyse the images is not known. We want to know if MRI gives reproducible measurements, and whether the MRI measurements are more reproducible than existing methods. The advantage of having a reproducible measurement allows small changes on treatment to be identified. This can benefit treatment decisions and pharma companies to develop new effective medications.
REC name
Yorkshire & The Humber - Bradford Leeds Research Ethics Committee
REC reference
15/YH/0269
Date of REC Opinion
23 Jul 2015
REC opinion
Further Information Favourable Opinion